IQVIA Holdings Inc. (NYSE:IQV) Stock Holdings Lessened by M&T Bank Corp

M&T Bank Corp lessened its position in IQVIA Holdings Inc. (NYSE:IQV) by 6.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 120,977 shares of the medical research company’s stock after selling 8,354 shares during the period. M&T Bank Corp owned approximately 0.07% of IQVIA worth $27,992,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of IQV. AMF Tjanstepension AB acquired a new stake in shares of IQVIA in the 3rd quarter worth about $148,096,000. Eagle Asset Management Inc. acquired a new stake in shares of IQVIA in the 3rd quarter worth about $102,982,000. iA Global Asset Management Inc. increased its holdings in shares of IQVIA by 1,225.3% in the 3rd quarter. iA Global Asset Management Inc. now owns 320,271 shares of the medical research company’s stock worth $63,013,000 after acquiring an additional 296,105 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of IQVIA by 2,765.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 271,316 shares of the medical research company’s stock worth $53,381,000 after acquiring an additional 261,848 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its holdings in shares of IQVIA by 33.4% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,039,436 shares of the medical research company’s stock worth $240,505,000 after acquiring an additional 260,271 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Up 0.6 %

Shares of IQV traded up $1.23 during midday trading on Friday, hitting $223.37. The stock had a trading volume of 1,052,929 shares, compared to its average volume of 831,136. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The business has a 50-day simple moving average of $244.56 and a two-hundred day simple moving average of $223.84. The firm has a market cap of $40.54 billion, a P/E ratio of 30.52, a price-to-earnings-growth ratio of 2.15 and a beta of 1.52. The company has a current ratio of 0.88, a quick ratio of 0.86 and a debt-to-equity ratio of 2.02.

IQVIA (NYSE:IQV) last announced its earnings results on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.82 by $0.02. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. The company had revenue of $3.87 billion during the quarter, compared to analysts’ expectations of $3.80 billion. During the same period last year, the company posted $2.54 earnings per share. The business’s revenue for the quarter was up 3.5% on a year-over-year basis. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 10.12 EPS for the current year.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of recent analyst reports. BTIG Research began coverage on shares of IQVIA in a research report on Tuesday, February 13th. They set a “buy” rating and a $285.00 price target on the stock. UBS Group increased their price target on IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a research note on Thursday, February 15th. Guggenheim downgraded IQVIA from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. Leerink Partnrs reaffirmed an “outperform” rating on shares of IQVIA in a research note on Monday, February 26th. Finally, Barclays lifted their target price on IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $257.57.

Insider Buying and Selling

In related news, insider Kevin C. Knightly sold 8,607 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the sale, the insider now directly owns 5,251 shares in the company, valued at $1,313,642.67. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, insider Eric Sherbet sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the sale, the insider now directly owns 20,836 shares in the company, valued at $5,031,894. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Kevin C. Knightly sold 8,607 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the sale, the insider now owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The disclosure for this sale can be found here. Over the last three months, insiders sold 41,285 shares of company stock worth $10,331,003. 1.60% of the stock is owned by company insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.